Literature DB >> 21119595

Functions of Fos phosphorylation in bone homeostasis, cytokine response and tumourigenesis.

L Bakiri1, M O Reschke, H A Gefroh, M H Idarraga, K Polzer, R Zenz, G Schett, E F Wagner.   

Abstract

Mice lacking c-fos develop osteopetrosis due to a block in osteoclast differentiation. Carboxy-terminal phosphorylation of Fos on serine 374 by ERK1/2 and serine 362 by RSK1/2 regulates Fos stability and transactivation potential in vitro. To assess the physiological relevance of Fos phosphorylation in vivo, serine 362 and/or serine 374 was replaced by alanine (Fos362A, Fos374A and FosAA) or by phospho-mimetic aspartic acid (FosDD). Homozygous mutants were healthy and skeletogenesis was largely unaffected. Fos C-terminal phosphorylation, predominantly on serine 374, was found important for osteoclast differentiation in vitro and affected lipopolysaccharide (LPS)-induced cytokine response in vitro and in vivo. Importantly, skin papilloma development was delayed in FosAA, Fos362A and Rsk2-deficient mice, accelerated in FosDD mice and unaffected in Fos374A mutants. Furthermore, the related Fos protein and putative RSK2 target Fra1 failed to substitute for Fos in papilloma development. This indicates that phosphorylation of serines 362 and 374 exerts context-dependent roles in modulating Fos activity in vivo. Inhibition of Fos C-terminal phosphorylation on serine 362 by targeting RSK2 might be of therapeutic relevance for skin tumours.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21119595      PMCID: PMC3838948          DOI: 10.1038/onc.2010.542

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

Review 1.  AP-1: a double-edged sword in tumorigenesis.

Authors:  Robert Eferl; Erwin F Wagner
Journal:  Nat Rev Cancer       Date:  2003-11       Impact factor: 60.716

2.  Conditional gene targeting in macrophages and granulocytes using LysMcre mice.

Authors:  B E Clausen; C Burkhardt; W Reith; R Renkawitz; I Förster
Journal:  Transgenic Res       Date:  1999-08       Impact factor: 2.788

3.  The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression.

Authors:  Patrizia Ferrara; Elisabetta Andermarcher; Guillaume Bossis; Claire Acquaviva; Frédérique Brockly; Isabelle Jariel-Encontre; Marc Piechaczyk
Journal:  Oncogene       Date:  2003-03-13       Impact factor: 9.867

4.  Fra-1 replaces c-Fos-dependent functions in mice.

Authors:  A Fleischmann; F Hafezi; C Elliott; C E Remé; U Rüther; E F Wagner
Journal:  Genes Dev       Date:  2000-11-01       Impact factor: 11.361

5.  Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor.

Authors:  Paula Monje; Maria Julia Marinissen; J Silvio Gutkind
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

6.  c-fos is required for malignant progression of skin tumors.

Authors:  E Saez; S E Rutberg; E Mueller; H Oppenheim; J Smoluk; S H Yuspa; B M Spiegelman
Journal:  Cell       Date:  1995-09-08       Impact factor: 41.582

7.  Molecular interpretation of ERK signal duration by immediate early gene products.

Authors:  Leon O Murphy; Sallie Smith; Rey-Huei Chen; Diane C Fingar; John Blenis
Journal:  Nat Cell Biol       Date:  2002-08       Impact factor: 28.824

8.  Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene.

Authors:  Alexander Fleischmann; Wolfram Jochum; Robert Eferl; James Witowsky; Erwin F Wagner
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

9.  Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS.

Authors:  Alexander Fleischmann; Oivind Hvalby; Vidar Jensen; Tatyana Strekalova; Christiane Zacher; Liliana E Layer; Ane Kvello; Markus Reschke; Rainer Spanagel; Rolf Sprengel; Erwin F Wagner; Peter Gass
Journal:  J Neurosci       Date:  2003-10-08       Impact factor: 6.167

10.  c-Jun regulates eyelid closure and skin tumor development through EGFR signaling.

Authors:  Rainer Zenz; Harald Scheuch; Paul Martin; Carsten Frank; Robert Eferl; Lukas Kenner; Maria Sibilia; Erwin F Wagner
Journal:  Dev Cell       Date:  2003-06       Impact factor: 12.270

View more
  6 in total

1.  Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17.

Authors:  Juan Guinea-Viniegra; Rainer Zenz; Harald Scheuch; María Jiménez; Latifa Bakiri; Peter Petzelbauer; Erwin F Wagner
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

2.  Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression.

Authors:  L Bakiri; S Macho-Maschler; I Custic; J Niemiec; A Guío-Carrión; S C Hasenfuss; A Eger; M Müller; H Beug; E F Wagner
Journal:  Cell Death Differ       Date:  2014-10-10       Impact factor: 15.828

3.  Terminal epidermal differentiation is regulated by the interaction of Fra-2/AP-1 with Ezh2 and ERK1/2.

Authors:  Stefanie Wurm; Jisheng Zhang; Juan Guinea-Viniegra; Fernando García; Javier Muñoz; Latifa Bakiri; Elena Ezhkova; Erwin F Wagner
Journal:  Genes Dev       Date:  2014-12-29       Impact factor: 11.361

4.  KDM2B/FBXL10 targets c-Fos for ubiquitylation and degradation in response to mitogenic stimulation.

Authors:  X-R Han; Z Zha; H-X Yuan; X Feng; Y-K Xia; Q-Y Lei; K-L Guan; Y Xiong
Journal:  Oncogene       Date:  2016-01-04       Impact factor: 9.867

5.  TPL-2 Inhibits IFN-β Expression via an ERK1/2-TCF-FOS Axis in TLR4-Stimulated Macrophages.

Authors:  Louise Blair; Michael J Pattison; Probir Chakravarty; Stamatia Papoutsopoulou; Latifa Bakiri; Erwin F Wagner; Stephen Smale; Steven C Ley
Journal:  J Immunol       Date:  2022-01-26       Impact factor: 5.426

6.  The Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Pathway in Osteoblasts.

Authors:  Matthew B Greenblatt; Jae-Hyuck Shim; Seoyeon Bok; Jung-Min Kim
Journal:  J Bone Metab       Date:  2022-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.